Yashoda Hospitals launches antibody cocktail drugs to treat Covid
The first batch of Covid positive patients were administered with the antibody cocktail at Yashoda Hospital Secunderabad on Wednesday
Hyderabad: Yashoda Hospitals in collaboration with Cipla on Wednesday has launched antibody cocktail Casirivimab and Imdevimab for treatment of Covid positive patients. The first batch of Covid positive patients were administered with the antibody cocktail at Yashoda Hospital Secunderabad on Wednesday.
In clinical trials on patients with Covid-19, the cocktail antibody combination of Casirivimab and Imdevimab, administered together, have shown to reduce Covid-19 related hospitalisation or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo. As with every drug benefits and risks need to be assessed individually and recommended to consult the primary care doctor or/and pulmonologist for indications for use and suitability, according to Dr. Lingaiah, medical director of Yashoda Hospitals.
It was observed in phase three clinical trials that the cocktail of the antibody drugs significantly reduced the risk of hospitalisation or death by at least 70 per cent and also also significantly shortened the duration of symptoms by four days.
This antibody cocktail drug is approved at a combined dose of 1200 mg (600 mg of each drug) administered by intravenous infusion or subcutaneous route on OP basis. It should be administered as soon as possible after onset of symptoms of even in asymptomatic patients. The drugs can also be administered to contacts of households who had Covid, as a prophylaxis so that the contacts do not get Covid.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
